Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Dapagliflozin vs Pioglitazone (Actos): Dapagliflozin has the stronger overall evidence (4.4 vs 4/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Dapagliflozin wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Dapagliflozin and Pioglitazone (Actos) have evidence — compare verdict strength side-by-side.
Off-label use mirrors approved dosing (10 mg once daily) under a clinician. A prescription drug; not an approved longevity regimen.
morning
Oral tablet (dapagliflozin)
Off-label metabolic use mirrors diabetes dosing (e.g. 15–45 mg once daily) under a clinician. A prescription drug; not an approved longevity regimen.
morning
Oral tablet (pioglitazone)
Months to years
Months to years
Weeks to months
Throughout use
Weeks to months
Months to years
Months
Throughout use
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
The New England journal of medicine (2019) · Rct · n=4744
DAPA-HF randomized trial in heart failure with reduced ejection fraction
Dapagliflozin in Patients with Chronic Kidney Disease.
The New England journal of medicine (2020) · Rct · n=4304
DAPA-CKD randomized trial in a broad, largely non-diabetic chronic-kidney-disease population
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
The New England journal of medicine (2022) · Rct · n=6263
DELIVER randomized trial extending dapagliflozin to mildly reduced and preserved ejection fraction
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
The New England journal of medicine (2016) · Rct · n=3876
IRIS randomized trial in patients with insulin resistance but no diabetes after recent stroke/TIA (n=3,876)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
Lancet (London, England) (2005) · Rct · n=5238
PROactive randomized trial in high-cardiovascular-risk type 2 diabetics (n=5,238)
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Annals of internal medicine (2016) · Rct
Randomized, placebo-controlled trial of long-term pioglitazone in NASH with prediabetes/type 2 diabetes
Dapagliflozin has a higher evidence score (4.4/10 vs 4/10) and wins in 1 of 3 categories.
For support heart health, Dapagliflozin has a higher relevance score (72 vs 55).
No known interactions between Dapagliflozin and Pioglitazone (Actos) have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.